ConforMIS Announces Promotion of Steven Armstrong to Vice President, Operations

BEDFORD, Mass., Dec. 23, 2015 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy, today announced the promotion of Steven Armstrong to the position of Vice President, Operations, effective December 22, 2015.

Mr. Armstrong joined the ConforMIS team in March 2015 as Senior Director, Operations, where he has been overseeing the manufacturing of customized joint replacement implants and instrumentation. During his tenure, Mr. Armstrong has demonstrated outstanding leadership and execution in operations and management. Mr. Armstrong offers exceptional experience in medical device manufacturing, as demonstrated by his 19 years at Palomar Medical Technologies, most recently as Senior Vice President of Operations.

In addition, ConforMIS today announced the resignation of Matthew Scott, Senior Vice President of Operations, effective December 31, 2015.

“We are very excited about the appointment of Steve Armstrong as VP Operations in view of the many years of medical device manufacturing experience that he brings to the table and the impact he’s had on our organization during his tenure at ConforMIS. We would like to thank Matt for his contributions to the growth and development of ConforMIS, and wish him the best in his future endeavors,” said Philipp Lang, CEO and President.

About ConforMIS, Inc.

ConforMIS is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient’s unique anatomy. ConforMIS offers a broad line of customized knee implants and pre-sterilized, single-use instruments delivered in a single package to the hospital. In recent clinical studies, ConforMIS iTotal CR demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. ConforMIS owns or exclusively in-licenses approximately 500 issued patents and pending patent applications that cover customized implants and patient-specific instrumentation for all major joints.

For more information, visit To receive future releases in e-mail alerts, sign up at

Cautionary Statement Regarding Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for ConforMIS, including statements about ConforMIS’s strategy, future operations, future financial position and results and expected market growth, including expectations regarding the potential impact and advantages of using customized implants, total revenue and revenue mix by product and geography, product gross margin and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our estimates regarding the potential market opportunity for our current and future products, our expectations regarding our sales, expenses, gross margins and other results of operations, and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent ConforMIS’s views as of the date hereof. ConforMIS anticipates that subsequent events and developments may cause ConforMIS’s views to change. However, while ConforMIS may elect to update these forward-looking statements at some point in the future, ConforMIS specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing ConforMIS’s views as of any date subsequent to the date hereof.

Investor contact Oksana Bradley (781) 374-5598

Source:ConforMIS, Inc